STOCK TITAN
  1. Home
  2. Sec-filings
  3. ICCM
  4. [Form 3] IceCure Medical Ltd. Initial Statement of Beneficial Ownership

IceCure Medical (ICCM) VP Naum Muchnik details insider share and option holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

IceCure Medical Ltd. officer Naum Muchnik, VP of R&D & Engineering, reports his current equity holdings in the company. He holds 118,621 ordinary shares directly, with no buy or sell transactions reported in this filing.

He also holds multiple option grants over ordinary shares, including 4,142 options at an exercise price of $2.27 per share expiring in 2029, 16,000 options at $1.79 expiring in 2029, 27,462 options at $1.56 expiring in 2030, 1,318 options at $5.78 expiring in 2031, 80,668 options at $3.64 expiring in 2032, 4,085 options at $2.84 expiring in 2032, 40,705 options at $1.51 expiring in 2033, and 90,945 options at $0.92 expiring in 2034.

Footnotes state that earlier grants are fully vested as of March 18, 2026, while more recent option and restricted share unit awards vest over time, with portions already vested and the remainder scheduled to vest in equal quarterly installments.

Positive

  • None.

Negative

  • None.
Insider Muchnik Naum
Role VP, R&D & Engineering
Type Security Shares Price Value
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Ordinary shares -- -- --
Holdings After Transaction: Share option (right to buy) — 4,142 shares (Direct); Ordinary shares — 118,621 shares (Direct)
Footnotes (1)
  1. Represents (i) 75,787 restricted share units ("RSUs") granted on July 2, 2024, 25% of which vest on July 29, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, and (ii) 42,834 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026. The options were granted on March 28, 2019, 25% of which vested on March 28, 2020, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 4,142 options are fully vested. The options were granted with an exercise price of NIS 7.04 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.27 per share. The options were granted on May 21, 2019, 25% of which vested on May 21, 2020, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 16,000 options are fully vested. The options were granted with an exercise price of NIS 5,536 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.79 per share. The options were granted on September 6, 2020, 25% of which vested on September 6, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 27,462 options are fully vested. The options were granted with an exercise price of NIS 4.84 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.56 per share. The options were granted on April 28, 2021, 25% of which vested on April 28, 2022 and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 1,318 options are fully vested. The options were granted with an exercise price of NIS 17.92 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $5.78 per share. The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 80,668 options are fully vested. The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share. The options were granted on March 23, 2022, 25% of which vested on March 23, 2023, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 3,829 are vested. The options were granted with an exercise price of NIS 8.81 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.84 per share. The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 30,528 options are vested. The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share. The options were granted on July 2, 2024, 25% of which vested on July 2, 2025, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 34,104 options are vested.
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Muchnik Naum
(Last)(First)(Middle)
7 HA'ESHEL ST., PO BOX 3163
(Street)
CAESAREA3079504
(City)(State)(Zip)
ISRAEL
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
IceCure Medical Ltd. [ ICCM ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
VP, R&D & Engineering
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares118,621(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Share option (right to buy) (2)03/28/2029Ordinary shares4,142$2.27(3)D
Share option (right to buy) (4)05/21/2029Ordinary shares16,000$1.79(5)D
Share option (right to buy) (6)08/30/2030Ordinary shares27,462$1.56(7)D
Share option (right to buy) (8)04/28/2031Ordinary shares1,318$5.78(9)D
Share option (right to buy) (10)01/12/2032Ordinary shares80,668$3.64(11)D
Share option (right to buy) (12)03/23/2032Ordinary shares4,085$2.84(13)D
Share option (right to buy) (14)02/19/2033Ordinary shares40,705$1.51(15)D
Share option (right to buy) (16)07/02/2034Ordinary shares90,945$0.92D
Explanation of Responses:
1. Represents (i) 75,787 restricted share units ("RSUs") granted on July 2, 2024, 25% of which vest on July 29, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, and (ii) 42,834 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026.
2. The options were granted on March 28, 2019, 25% of which vested on March 28, 2020, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 4,142 options are fully vested.
3. The options were granted with an exercise price of NIS 7.04 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.27 per share.
4. The options were granted on May 21, 2019, 25% of which vested on May 21, 2020, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 16,000 options are fully vested.
5. The options were granted with an exercise price of NIS 5,536 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.79 per share.
6. The options were granted on September 6, 2020, 25% of which vested on September 6, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 27,462 options are fully vested.
7. The options were granted with an exercise price of NIS 4.84 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.56 per share.
8. The options were granted on April 28, 2021, 25% of which vested on April 28, 2022 and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 1,318 options are fully vested.
9. The options were granted with an exercise price of NIS 17.92 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $5.78 per share.
10. The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 80,668 options are fully vested.
11. The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share.
12. The options were granted on March 23, 2022, 25% of which vested on March 23, 2023, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 3,829 are vested.
13. The options were granted with an exercise price of NIS 8.81 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.84 per share.
14. The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 30,528 options are vested.
15. The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.
16. The options were granted on July 2, 2024, 25% of which vested on July 2, 2025, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 34,104 options are vested.
/s/ Naum Muchnik03/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider position does Naum Muchnik hold at IceCure Medical (ICCM)?

Naum Muchnik is an officer at IceCure Medical, serving as VP, R&D & Engineering. This senior R&D leadership role explains why he holds a mix of ordinary shares, options, and restricted share units as part of his overall compensation package.

How many IceCure Medical (ICCM) ordinary shares does Naum Muchnik hold?

Naum Muchnik directly holds 118,621 ordinary shares of IceCure Medical. These are recorded as direct ownership and reflect his current share position, separate from his option grants and restricted share unit awards disclosed alongside them in the same filing.

What stock options over IceCure Medical (ICCM) shares does Naum Muchnik report?

He reports several option grants over ordinary shares, including 4,142 options at $2.27, 16,000 at $1.79, 27,462 at $1.56, 80,668 at $3.64, and other smaller grants, each with specific expiration dates between 2029 and 2034.

Are Naum Muchnik’s IceCure Medical (ICCM) options vested or unvested?

Footnotes state earlier option grants are fully vested as of March 18, 2026, while later grants vest over time. For newer awards, only a portion is vested and the remaining options continue vesting in equal quarterly installments of 6.25%.

What restricted share units (RSUs) in IceCure Medical (ICCM) does Naum Muchnik have?

He has 75,787 RSUs granted on July 2, 2024 and 42,834 RSUs granted on November 5, 2025. All these RSUs remain unvested as of March 18, 2026, with vesting schedules starting one year after each grant date.

Does this IceCure Medical (ICCM) insider filing show any recent share purchases or sales?

No buy or sell transactions are reported for Naum Muchnik in this filing. The entries are labeled as holdings, meaning they summarize his existing ordinary share, option, and RSU positions rather than new market trades in IceCure Medical stock.